Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Differentiating the cellular and humoral components of neuromuscular blocking agent-induced anaphylactic reactions in patients undergoing anaesthesia.

Aalberse RC, Kleine Budde I, Mulder M, Stapel SO, Paulij W, Leynadier F, Hollmann MW.

Br J Anaesth. 2011 May;106(5):665-74. doi: 10.1093/bja/aer028. Epub 2011 Mar 17.

2.

Comparison of analytical methods to detect instability of etanercept during thermal stress testing.

Maarschalkerweerd Av, Wolbink GJ, Stapel SO, Jiskoot W, Hawe A.

Eur J Pharm Biopharm. 2011 Jun;78(2):213-21. doi: 10.1016/j.ejpb.2011.01.012. Epub 2011 Jan 24.

PMID:
21272639
3.

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.

Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ.

Ann Rheum Dis. 2011 Feb;70(2):284-8. doi: 10.1136/ard.2010.135111. Epub 2010 Nov 10.

PMID:
21068090
4.

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis.

van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP.

Ann Rheum Dis. 2010 Mar;69(3):624-5. doi: 10.1136/ard.2009.108787. No abstract available.

PMID:
20223840
5.

Anti-epoetin-antibody-induced anemia in a child with chronic renal failure.

Jöbsis JJ, Fijnvandraat K, Stapel SO, Bouts AH.

Pediatr Nephrol. 2010 May;25(5):993-4. doi: 10.1007/s00467-010-1442-0. Epub 2010 Feb 18. No abstract available.

6.

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, Bos JD, Wolbink GJ.

Arch Dermatol. 2010 Feb;146(2):127-32. doi: 10.1001/archdermatol.2009.347.

PMID:
20157022
7.

A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.

van den Bemt BJ, Vos K, den Broeder AA, Blom M, Thurlings RM, Bartelds GM, Stapel SO, Barrera P, Tak PP, Nurmohamed MT, Wolbink GJ.

Ann Rheum Dis. 2009 Aug;68(8):1368-9. doi: 10.1136/ard.2008.095448. No abstract available.

PMID:
19605744
8.

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis.

Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, van Laar JM, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2010 Feb;69(2):409-12. doi: 10.1136/ard.2009.109041. Epub 2009 Jul 12.

PMID:
19596693
9.

Immunoglobulin G4: an odd antibody.

Aalberse RC, Stapel SO, Schuurman J, Rispens T.

Clin Exp Allergy. 2009 Apr;39(4):469-77. doi: 10.1111/j.1365-2222.2009.03207.x. Epub 2009 Feb 13. Review.

PMID:
19222496
10.

Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report.

Stapel SO, Asero R, Ballmer-Weber BK, Knol EF, Strobel S, Vieths S, Kleine-Tebbe J; EAACI Task Force.

Allergy. 2008 Jul;63(7):793-6. doi: 10.1111/j.1398-9995.2008.01705.x. Epub 2008 May 16.

PMID:
18489614
11.

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.

de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ.

Ann Rheum Dis. 2009 Apr;68(4):531-5. doi: 10.1136/ard.2008.089979. Epub 2008 Mar 28.

PMID:
18375542
12.

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.

de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE.

Ann Rheum Dis. 2007 Sep;66(9):1252-4. Epub 2007 May 1.

13.

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.

de Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE.

Ann Rheum Dis. 2007 Jan;66(1):133-4. No abstract available.

14.

Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy.

Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, Maillere B, Kay AB, Larché M.

Clin Exp Allergy. 2006 Apr;36(4):465-74.

PMID:
16630151
15.

Immunoglobulin E and G4 antibody responses in occupational airway exposure to bovine and porcine plasma proteins.

Krop EJ, Stapel SO, De Vrieze H, Van der Zee JS.

Int Arch Allergy Immunol. 2006;139(3):237-44. Epub 2006 Jan 27.

PMID:
16446546
16.

Coughing in pre-school children in general practice: when are RAST's for inhalation allergy indicated?

Eysink PE, Bottema BJ, ter Riet G, Aalberse RC, Stapel SO, Bindels PJ.

Pediatr Allergy Immunol. 2004 Oct;15(5):394-400.

PMID:
15482513
17.

IgE testing in capillary blood.

Stapel SO, Eysink PE, Vrieze J, Aalberse RC.

Pediatr Allergy Immunol. 2004 Jun;15(3):230-3.

PMID:
15209955
18.

IgE to Bet v 1 and profilin: cross-reactivity patterns and clinical relevance.

Wensing M, Akkerdaas JH, van Leeuwen WA, Stapel SO, Bruijnzeel-Koomen CA, Aalberse RC, Bast BJ, Knulst AC, van Ree R.

J Allergy Clin Immunol. 2002 Sep;110(3):435-42.

PMID:
12209091
19.

Do levels of immunoglobulin G antibodies to foods predict the development of immunoglobulin E antibodies to cat, dog and/or mite?

Eysink PE, Bindels PJ, Stapel SO, Bottema BJ, Van Der Zee JS, Aalberse RC.

Clin Exp Allergy. 2002 Apr;32(4):556-62.

PMID:
11972602
20.

Inadvertent BSA-induced elution of IgE in the BSA-RAST.

Kleine Budde I, de Heer PG, Stapel SO, van der Zee JS, Aalberse RC.

Allergy. 2001 Nov;56(11):1055-60.

Supplemental Content

Loading ...
Support Center